Keros Therapeutics, Inc. (KROS) stock
KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$11.31+1.28 (+12.76%)
Close on Nov 17, 2026Market cap $224.25MP/E –Yield –
Keros Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Keros Therapeutics's price to book ratio was 0.7× on Nov 11, 2026, against 1.0× a year earlier. Over the last 5 years it ranged from 0.7× to 6.5×, with a median of 3.4×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 0.7× | −0.5 |
| 2025 | Dec 31, 2025 | 1.2× | +0.0 |
| 2024 | Dec 31, 2024 | 1.2× | −2.8 |
| 2023 | Dec 29, 2023 | 4.0× | −1.2 |
| 2022 | Dec 30, 2022 | 5.2× | −1.1 |
| 2021 | Dec 31, 2021 | 6.3× | −4.6 |
| 2020 | Dec 31, 2020 | 10.9× | – |
See a number that looks wrong?